Safety of Topical Exosome-Containing Liquid in Healthy Volunteers (EV-SAFE-1)
sunnuntai 12. heinäkuuta 2026 päivittänyt: Amin Tamadon, West Kazakhstan Marat Ospanov Medical University
A Phase 1 Split-Site Pilot Study to Evaluate the Safety and Dermal Tolerability of Topical Exosome-Containing Liquid in Healthy Adult Volunteers
This Phase 1 split-site pilot study will evaluate the safety and dermal tolerability of a topical exosome-containing liquid in 10 healthy adult volunteers.
The investigational liquid will be applied to a small defined area of intact skin.
A vehicle liquid without exosomes may be applied to a matched contralateral skin site as a control.
The study will assess local skin reactions, systemic adverse events, vital signs, clinical laboratory parameters, and feasibility of topical administration.
No burn wound or artificial skin wound will be induced in participants in this Phase 1 safety study.
Tutkimuksen yleiskatsaus
Tila
Ei vielä rekrytointia
Interventio / Hoito
Yksityiskohtainen kuvaus
The investigational product is a sterile topical exosome-containing liquid being developed for future evaluation in burn wound repair. Preclinical in vivo evaluation in murine wound models suggested improved wound closure and better histological organization of repaired skin after topical exosome-containing formulation administration, with the therapeutic effect being more pronounced in the thermal burn model. In the burn model, the exosome-containing formulation group showed faster wound-area reduction, improved epidermal and dermal organization, reduced inflammatory cellularity, and no significant body-weight differences compared with control groups.
This first-in-human Phase 1 study is designed to evaluate safety and dermal tolerability in healthy adult volunteers before the product is tested in patients with burn wounds. No artificial burn wound or skin wound will be created. The investigational liquid will be applied to a small defined area of intact skin according to the protocol-defined dose and schedule. If a split-site design is used, vehicle liquid without exosomes will be applied to a matched contralateral intact skin site as a control. Participants will be monitored for local skin irritation, erythema, edema, pruritus, burning sensation, pain, rash, allergic reaction, systemic adverse events, vital signs, and clinical laboratory abnormalities.
The first two participants will be enrolled as sentinel participants. Safety data through at least 72 hours after first application will be reviewed before enrollment of the remaining participants. The main purpose of the study is to determine whether topical administration of the exosome-containing liquid is safe and tolerable on intact human skin.
Opintotyyppi
Interventio
Ilmoittautuminen (Arvioitu)
10
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskeluyhteys
- Nimi: Nadiar M Mussin, PhD
- Puhelinnumero: +7 777 297 8901
- Sähköposti: nadiar_musin@zkmu.kz
Tutki yhteystietojen varmuuskopiointi
- Nimi: Amin Tamadon, PhD
- Puhelinnumero: +7 705 629 9350
- Sähköposti: tamadon@zkmu.kz
Opiskelupaikat
-
-
Aktobe
-
Aktobe, Aktobe, Kazakstan, 030012
- ATMP center of West Kazakhstan Marat Ospanov Medical University
-
Ottaa yhteyttä:
- Nadiar M Mussin, PhD
- Puhelinnumero: +7 777 297 8901
- Sähköposti: nadiar_musin@zkmu.kz
-
Ottaa yhteyttä:
- Amin Tamadon, PhD
- Puhelinnumero: 87056299350
- Sähköposti: amintamaddon@yahoo.com
-
Päätutkija:
- Amin Tamadon, PhD
-
Päätutkija:
- Nadiar M Mussin, PhD
-
Päätutkija:
- Mahdi Mahdipour, PhD
-
Alatutkija:
- Kulyash R. Zhilisbayeva, MSc
-
Alatutkija:
- Ogay V. Borisovich, PhD
-
Alatutkija:
- Nader Tanideh, PhD
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
Hyväksyy terveitä vapaaehtoisia
Joo
Kuvaus
Inclusion Criteria:
- Healthy adult volunteers aged 18 to 55 years.
- Able and willing to provide written informed consent.
- No clinically significant abnormality based on medical history, physical examination, vital signs, and screening laboratory tests.
- Intact healthy skin at the planned application sites.
- Willingness to avoid applying other topical products, cosmetics, antiseptics, or irritant substances to the application sites during the study period.
- Willingness to avoid excessive sun exposure, sauna, swimming pool use, and mechanical irritation of the application sites during the study period.
- Willingness to comply with all study visits, topical application procedures, local skin assessments, skin photography, safety assessments, and follow-up.
- For women of childbearing potential, a negative pregnancy test before first application and willingness to use an acceptable method of contraception during the study period.
Exclusion Criteria:
- Any active skin disease, dermatitis, eczema, psoriasis, urticaria, acneiform eruption, skin infection, open wound, scar, tattoo, burn scar, pigmentation disorder, or clinically significant skin abnormality at the planned application sites.
- History of severe allergy, anaphylaxis, or hypersensitivity to topical liquids, dressings, biological products, exosome-containing products, or any component of the investigational product or vehicle liquid.
- Current acute illness, fever, or active infection.
- Known autoimmune disease, immunodeficiency, or current systemic immunosuppressive therapy.
- Use of systemic corticosteroids, immunomodulatory drugs, biological agents, or investigational products within 30 days before enrollment.
- Use of topical corticosteroids, topical immunomodulators, topical antibiotics, retinoids, keratolytic agents, or other medicated topical products on or near the planned application sites within 14 days before enrollment.
- Clinically significant hepatic, renal, cardiovascular, hematologic, endocrine, neurologic, psychiatric, or systemic disease that may increase risk or interfere with interpretation of study results.
- Known active malignancy or history of malignancy within the past 5 years.
- Positive screening test for clinically relevant transmissible infection, if required by the protocol.
- Pregnancy or breastfeeding.
- Positive pregnancy test at screening or before first application in women of childbearing potential.
- Participation in another interventional clinical trial within 30 days before enrollment.
- Blood donation or major blood loss within 30 days before enrollment, if laboratory safety monitoring is included in the protocol.
- Any condition that, in the investigator's judgment, would make participation unsafe or interfere with interpretation of study results.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Exosome-Containing Liquid and Vehicle-Control Skin Sites
Healthy adult volunteers will receive topical exosome-containing liquid applied to a small defined area of intact skin.
In the split-site design, vehicle liquid without exosomes will be applied to a matched contralateral intact skin site as a control.
No burn wound or artificial skin wound will be induced.
|
The investigational product is a sterile topical liquid containing exosome-enriched extracellular vesicles derived from [insert cell source, e.g., mesenchymal stromal cells].
The liquid will be applied topically to a small defined area of intact skin at a dose of [insert exact dose, e.g., X mL/cm² containing Y particles/mL, equivalent to Z particles/cm²] according to the protocol-defined schedule.
The product is investigational and is being evaluated for safety and dermal tolerability before future testing in patients with burn wounds.
Muut nimet:
Vehicle liquid without exosomes will be applied topically to a matched contralateral intact skin site according to the same protocol-defined schedule as the exosome-containing liquid.
The vehicle liquid is used as a within-participant control for local dermal tolerability assessment.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events
Aikaikkuna: From first application through Day 28
|
Number of participants with any treatment-emergent adverse event after topical application of the exosome-containing liquid.
Events include local application-site reactions such as erythema, edema, pruritus, burning sensation, pain, rash, vesicles, ulceration, allergic reaction, or infection, and systemic events such as fever, malaise, abnormal vital signs, clinically significant laboratory abnormalities, serious adverse events, or any other clinically significant adverse event judged by the investigator.
|
From first application through Day 28
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Maximum Total Score on the Draize Dermal Irritation Scale at the Exosome-Containing Liquid Application Site
Aikaikkuna: Baseline, 30 minutes, 24 hours, 48 hours, 72 hours, Day 7, Day 14, and Day 28
|
The Draize Dermal Irritation Scale grades erythema and eschar formation from 0, indicating no erythema, to 4, indicating severe erythema or eschar formation, and edema from 0, indicating no edema, to 4, indicating severe edema.
The total score is the sum of the erythema/eschar score and edema score and ranges from 0 to 8. Higher scores indicate worse local skin irritation.
The maximum total score observed at the exosome-containing liquid application site will be reported.
|
Baseline, 30 minutes, 24 hours, 48 hours, 72 hours, Day 7, Day 14, and Day 28
|
|
Within-Participant Difference in Total Draize Dermal Irritation Scale Score Between Exosome-Containing Liquid and Vehicle-Control Sites
Aikaikkuna: Baseline, 30 minutes, 24 hours, 48 hours, 72 hours, Day 7, Day 14, and Day 28
|
The within-participant difference will be calculated as the total Draize Dermal Irritation Scale score at the exosome-containing liquid application site minus the total score at the vehicle-control liquid application site at each assessment time point.
The total Draize score ranges from 0 to 8, with higher scores indicating worse local skin irritation.
Positive values indicate higher irritation at the exosome-containing liquid site, and negative values indicate higher irritation at the vehicle-control site.
|
Baseline, 30 minutes, 24 hours, 48 hours, 72 hours, Day 7, Day 14, and Day 28
|
|
Number of Participants With Clinically Significant Vital Sign Abnormalities
Aikaikkuna: From first application through Day 28
|
Number of participants with any clinically significant abnormality in vital signs after topical application of the exosome-containing liquid.
Vital signs include systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate, and body temperature.
Clinical significance will be determined by the investigator using protocol-defined reference ranges and clinical judgment.
The reporting unit is number of participants.
|
From first application through Day 28
|
|
Number of Participants With Clinically Significant Clinical Laboratory Abnormalities
Aikaikkuna: From first application through Day 28
|
Number of participants with any clinically significant abnormality in clinical laboratory safety tests after topical application of the exosome-containing liquid.
Laboratory safety tests include complete blood count, renal function tests, liver function tests, and inflammatory markers according to the protocol.
Clinical significance will be determined by the investigator using protocol-defined reference ranges and clinical judgment.
The reporting unit is number of participants.
|
From first application through Day 28
|
|
Percentage of Planned Topical Applications Completed According to Protocol
Aikaikkuna: From Day 0 through Day 14
|
For each participant, the topical application completion percentage will be calculated as the number of completed topical applications divided by the number of protocol-planned topical applications, multiplied by 100.
The outcome will be reported as the mean percentage of planned topical applications completed across participants.
A higher percentage indicates better feasibility of topical application.
|
From Day 0 through Day 14
|
|
Number of Participants With Delayed Treatment-Emergent Adverse Events
Aikaikkuna: From Day 29 through Day 56
|
Number of participants with delayed local or systemic treatment-emergent adverse events occurring after completion of the primary Day 28 safety assessment.
Delayed events may include local skin reactions, allergic reactions, infection, abnormal vital signs, clinically significant laboratory abnormalities, serious adverse events, or any other clinically significant adverse event judged by the investigator.
|
From Day 29 through Day 56
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Yleiset julkaisut
- Wang M, Xu X, Lei X, Tan J, Xie H. Mesenchymal stem cell-based therapy for burn wound healing. Burns Trauma. 2021 May 1;9:tkab002. doi: 10.1093/burnst/tkab002. eCollection 2021.
- Manzoor T, Farooq N, Sharma A, Shiekh PA, Hassan A, Dar LA, Nazir J, Godha M, Sheikh FA, Gugjoo MB, Saleem S, Ahmad SM. Exosomes in nanomedicine: a promising cell-free therapeutic intervention in burn wounds. Stem Cell Res Ther. 2024 Oct 9;15(1):355. doi: 10.1186/s13287-024-03970-3.
- Hu JC, Zheng CX, Sui BD, Liu WJ, Jin Y. Mesenchymal stem cell-derived exosomes: A novel and potential remedy for cutaneous wound healing and regeneration. World J Stem Cells. 2022 May 26;14(5):318-329. doi: 10.4252/wjsc.v14.i5.318.
- Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, Cai H, Di Vizio D, Driedonks TAP, Erdbrugger U, Falcon-Perez JM, Fu QL, Hill AF, Lenassi M, Lim SK, Mahoney MG, Mohanty S, Moller A, Nieuwland R, Ochiya T, Sahoo S, Torrecilhas AC, Zheng L, Zijlstra A, Abuelreich S, Bagabas R, Bergese P, Bridges EM, Brucale M, Burger D, Carney RP, Cocucci E, Crescitelli R, Hanser E, Harris AL, Haughey NJ, Hendrix A, Ivanov AR, Jovanovic-Talisman T, Kruh-Garcia NA, Ku'ulei-Lyn Faustino V, Kyburz D, Lasser C, Lennon KM, Lotvall J, Maddox AL, Martens-Uzunova ES, Mizenko RR, Newman LA, Ridolfi A, Rohde E, Rojalin T, Rowland A, Saftics A, Sandau US, Saugstad JA, Shekari F, Swift S, Ter-Ovanesyan D, Tosar JP, Useckaite Z, Valle F, Varga Z, van der Pol E, van Herwijnen MJC, Wauben MHM, Wehman AM, Williams S, Zendrini A, Zimmerman AJ; MISEV Consortium; Thery C, Witwer KW. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024 Feb;13(2):e12404. doi: 10.1002/jev2.12404.
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Tiistai 1. syyskuuta 2026
Ensisijainen valmistuminen (Arvioitu)
Tiistai 1. joulukuuta 2026
Opintojen valmistuminen (Arvioitu)
Perjantai 1. tammikuuta 2027
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Tiistai 7. heinäkuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Sunnuntai 12. heinäkuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Keskiviikko 15. heinäkuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Keskiviikko 15. heinäkuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Sunnuntai 12. heinäkuuta 2026
Viimeksi vahvistettu
Keskiviikko 1. heinäkuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- WKMU-EV-SAFE-001
- IRN BR25593457 (Muu apuraha/rahoitusnumero: Ministry of Healthcare of the Republic of Kazakhstan)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
EI
IPD-suunnitelman kuvaus
No. Individual participant data will not be shared because this is a small Phase 1 first-in-human safety and dermal tolerability study in 10 healthy volunteers, and de-identified individual-level data may still carry a risk of participant re-identification.
Aggregate study results, adverse event summaries, and protocol-defined outcome summaries may be reported in ClinicalTrials.gov
and in peer-reviewed publications.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .